View Financial HealthKBC Corporation 配当と自社株買い配当金 基準チェック /06KBC現在配当金を支払っていません。主要情報0%配当利回り-0.8%バイバック利回り総株主利回り-0.8%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向0%最近の配当と自社株買いの更新お知らせ • Aug 09KBC Corporation, Ltd. (SHSE:688598) commences an Equity Buyback Plan for CNY 20 million worth of its shares, under the authorization approved on August 6, 2024.KBC Corporation, Ltd. (SHSE:688598) commences share repurchases on August 8, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on August 6, 2024. As per the mandate, the company is authorized to repurchase to repurchase CNY 20 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 35 per share. The shares repurchased will be used to reduce registered capital, used for employee stock ownership plan or equity incentive, used to convert company convertible bonds and to maintain company value and shareholder rights. The program will be funded out of the company's own funds. The program will be valid till 1 months from the date of approval by shareholders, i.e., till September 5, 2024.お知らせ • Feb 27KBC Corporation, Ltd. (SHSE:688598) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on February 23, 2024.KBC Corporation, Ltd. (SHSE:688598) commences share repurchases on February 26, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on February 23, 2023. As per the mandate, the company is authorized to repurchase to repurchase CNY 100 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 90 per share. The repurchased shares will be cancelled. The program will be funded out of the company's own funds. The program will be valid till 1 months from the date of approval by shareholders.お知らせ • Sep 27KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 100 million worth of its shares.KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 3 months.お知らせ • May 30KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 100 million worth of its shares.KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 3 months.すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Jie Li was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 29KBC Corporation, Ltd., Annual General Meeting, May 20, 2026KBC Corporation, Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: 1F, No. 79, Xiaoshitang Road, Yuelu District, Changsha, Hunan Chinaお知らせ • Mar 30KBC Corporation, Ltd. to Report Q1, 2026 Results on Apr 29, 2026KBC Corporation, Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026お知らせ • Dec 26KBC Corporation, Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026KBC Corporation, Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026お知らせ • Sep 30KBC Corporation, Ltd. to Report Q3, 2025 Results on Oct 30, 2025KBC Corporation, Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025お知らせ • Jun 30KBC Corporation, Ltd. to Report First Half, 2025 Results on Aug 29, 2025KBC Corporation, Ltd. announced that they will report first half, 2025 results on Aug 29, 2025お知らせ • Apr 29KBC Corporation, Ltd., Annual General Meeting, May 20, 2025KBC Corporation, Ltd., Annual General Meeting, May 20, 2025, at 14:00 China Standard Time.お知らせ • Mar 28KBC Corporation, Ltd. to Report Q1, 2025 Results on Apr 29, 2025KBC Corporation, Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025お知らせ • Dec 27KBC Corporation, Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025KBC Corporation, Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025Reported Earnings • Oct 30Third quarter 2024 earnings released: CN¥0.21 loss per share (vs CN¥0.14 profit in 3Q 2023)Third quarter 2024 results: CN¥0.21 loss per share (down from CN¥0.14 profit in 3Q 2023). Revenue: CN¥97.3m (down 64% from 3Q 2023). Net loss: CN¥42.8m (down 248% from profit in 3Q 2023). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Sep 30KBC Corporation, Ltd. to Report Q3, 2024 Results on Oct 30, 2024KBC Corporation, Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024お知らせ • Aug 09KBC Corporation, Ltd. (SHSE:688598) commences an Equity Buyback Plan for CNY 20 million worth of its shares, under the authorization approved on August 6, 2024.KBC Corporation, Ltd. (SHSE:688598) commences share repurchases on August 8, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on August 6, 2024. As per the mandate, the company is authorized to repurchase to repurchase CNY 20 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 35 per share. The shares repurchased will be used to reduce registered capital, used for employee stock ownership plan or equity incentive, used to convert company convertible bonds and to maintain company value and shareholder rights. The program will be funded out of the company's own funds. The program will be valid till 1 months from the date of approval by shareholders, i.e., till September 5, 2024.お知らせ • Jun 28KBC Corporation, Ltd. to Report First Half, 2024 Results on Aug 30, 2024KBC Corporation, Ltd. announced that they will report first half, 2024 results on Aug 30, 2024New Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (31% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Profit margins are more than 30% lower than last year (3.1% net profit margin).お知らせ • Apr 30KBC Corporation, Ltd., Annual General Meeting, May 20, 2024KBC Corporation, Ltd., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: 1F, No. 79, Xiaoshitang Road, Yuelu District, Changsha, Hunan ChinaReported Earnings • Apr 29Full year 2023 earnings released: EPS: CN¥1.46 (vs CN¥4.36 in FY 2022)Full year 2023 results: EPS: CN¥1.46 (down from CN¥4.36 in FY 2022). Revenue: CN¥1.07b (down 26% from FY 2022). Net income: CN¥202.5m (down 63% from FY 2022). Profit margin: 19% (down from 38% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 65% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.Valuation Update With 7 Day Price Move • Apr 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥42.45, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 66% over the past year.お知らせ • Mar 29KBC Corporation, Ltd. to Report Q1, 2024 Results on Apr 29, 2024KBC Corporation, Ltd. announced that they will report Q1, 2024 results on Apr 29, 2024Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥55.50, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 54% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥96.72 per share.お知らせ • Feb 27KBC Corporation, Ltd. (SHSE:688598) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on February 23, 2024.KBC Corporation, Ltd. (SHSE:688598) commences share repurchases on February 26, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on February 23, 2023. As per the mandate, the company is authorized to repurchase to repurchase CNY 100 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 90 per share. The repurchased shares will be cancelled. The program will be funded out of the company's own funds. The program will be valid till 1 months from the date of approval by shareholders.Reported Earnings • Feb 24Full year 2023 earnings released: EPS: CN¥1.46 (vs CN¥4.36 in FY 2022)Full year 2023 results: EPS: CN¥1.46 (down from CN¥4.36 in FY 2022). Revenue: CN¥1.07b (down 26% from FY 2022). Net income: CN¥203.3m (down 63% from FY 2022). Profit margin: 19% (down from 38% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 55% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.Valuation Update With 7 Day Price Move • Jan 31Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥45.84, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 14x in the Chemicals industry in China. Total loss to shareholders of 72% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥88.43 per share.New Risk • Jan 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.8% average weekly change). High level of non-cash earnings (41% accrual ratio).Buying Opportunity • Dec 11Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be CN¥91.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Earnings per share has grown by 23%. Revenue is forecast to grow by 201% in 2 years. Earnings is forecast to grow by 156% in the next 2 years.New Risk • Nov 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (41% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).Reported Earnings • Oct 24Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.98 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.21 (down from CN¥0.98 in 3Q 2022). Revenue: CN¥271.1m (down 9.7% from 3Q 2022). Net income: CN¥28.8m (down 78% from 3Q 2022). Profit margin: 11% (down from 43% in 3Q 2022). Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China.お知らせ • Sep 27KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 100 million worth of its shares.KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 3 months.Reported Earnings • Aug 15Second quarter 2023 earnings released: EPS: CN¥1.20 (vs CN¥1.39 in 2Q 2022)Second quarter 2023 results: EPS: CN¥1.20 (down from CN¥1.39 in 2Q 2022). Revenue: CN¥304.6m (down 23% from 2Q 2022). Net income: CN¥165.1m (flat on 2Q 2022). Profit margin: 54% (up from 42% in 2Q 2022). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.お知らせ • Jun 28KBC Corporation, Ltd. to Report First Half, 2023 Results on Aug 29, 2023KBC Corporation, Ltd. announced that they will report first half, 2023 results on Aug 29, 2023New Risk • Jun 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (53% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding).お知らせ • May 30KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 100 million worth of its shares.KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 3 months.Reported Earnings • Apr 22Full year 2022 earnings released: EPS: CN¥6.45 (vs CN¥6.26 in FY 2021)Full year 2022 results: EPS: CN¥6.45 (up from CN¥6.26 in FY 2021). Revenue: CN¥1.45b (up 8.4% from FY 2021). Net income: CN¥551.2m (up 10.0% from FY 2021). Profit margin: 38% (in line with FY 2021). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.Reported Earnings • Mar 01Full year 2022 earnings released: EPS: CN¥6.45 (vs CN¥6.26 in FY 2021)Full year 2022 results: EPS: CN¥6.45 (up from CN¥6.26 in FY 2021). Revenue: CN¥1.45b (up 8.4% from FY 2021). Net income: CN¥551.2m (up 10.0% from FY 2021). Profit margin: 38% (in line with FY 2021). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Hongbo Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥265, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 15x in the Chemicals industry in China.Reported Earnings • Oct 30Third quarter 2022 earnings released: EPS: CN¥1.46 (vs CN¥1.63 in 3Q 2021)Third quarter 2022 results: EPS: CN¥1.46 (down from CN¥1.63 in 3Q 2021). Revenue: CN¥300.2m (down 20% from 3Q 2021). Net income: CN¥128.8m (down 1.3% from 3Q 2021). Profit margin: 43% (up from 35% in 3Q 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.Reported Earnings • Aug 29Second quarter 2022 earnings released: EPS: CN¥2.06 (vs CN¥1.58 in 2Q 2021)Second quarter 2022 results: EPS: CN¥2.06 (up from CN¥1.58 in 2Q 2021). Revenue: CN¥396.3m (up 27% from 2Q 2021). Net income: CN¥165.3m (up 30% from 2Q 2021). Profit margin: 42% (up from 41% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 26%, compared to a 40% growth forecast for the Chemicals industry in China.Valuation Update With 7 Day Price Move • Aug 02Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥381, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 18x in the Chemicals industry in China.Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥330, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 17x in the Chemicals industry in China.Valuation Update With 7 Day Price Move • May 02Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥214, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 15x in the Chemicals industry in China.Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: CN¥2.53 (vs CN¥0.97 in 1Q 2021)First quarter 2022 results: EPS: CN¥2.53 (up from CN¥0.97 in 1Q 2021). Revenue: CN¥450.2m (up 126% from 1Q 2021). Net income: CN¥202.7m (up 163% from 1Q 2021). Profit margin: 45% (up from 39% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 21%, compared to a 43% growth forecast for the industry in China.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Hongbo Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Mar 08Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to CN¥222, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 18x in the Chemicals industry in China.Reported Earnings • Feb 27Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: CN¥6.26 (up from CN¥2.35 in FY 2020). Revenue: CN¥1.34b (up 214% from FY 2020). Net income: CN¥501.1m (up 197% from FY 2020). Profit margin: 38% (down from 40% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 9.7%. Over the next year, revenue is forecast to grow 27%, compared to a 47% growth forecast for the industry in China.Valuation Update With 7 Day Price Move • Jan 11Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥298, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 20x in the Chemicals industry in China.決済の安定と成長配当データの取得安定した配当: 688598の 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 688598の配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場KBC Corporation 配当利回り対市場688598 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (688598)0%市場下位25% (CN)0.4%市場トップ25% (CN)1.9%業界平均 (Chemicals)1.2%アナリスト予想 (688598) (最長3年)0%注目すべき配当: 688598は最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 688598は最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 688598 CN市場において目立った配当金を支払っていません。株主配当金キャッシュフローカバレッジ: 688598が配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YCN 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 12:53終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋KBC Corporation, Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Xianfan ChenChina International Capital Corporation LimitedBai Qiao XuHaitong International Research LimitedJun LiuHuatai Research2 その他のアナリストを表示
お知らせ • Aug 09KBC Corporation, Ltd. (SHSE:688598) commences an Equity Buyback Plan for CNY 20 million worth of its shares, under the authorization approved on August 6, 2024.KBC Corporation, Ltd. (SHSE:688598) commences share repurchases on August 8, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on August 6, 2024. As per the mandate, the company is authorized to repurchase to repurchase CNY 20 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 35 per share. The shares repurchased will be used to reduce registered capital, used for employee stock ownership plan or equity incentive, used to convert company convertible bonds and to maintain company value and shareholder rights. The program will be funded out of the company's own funds. The program will be valid till 1 months from the date of approval by shareholders, i.e., till September 5, 2024.
お知らせ • Feb 27KBC Corporation, Ltd. (SHSE:688598) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on February 23, 2024.KBC Corporation, Ltd. (SHSE:688598) commences share repurchases on February 26, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on February 23, 2023. As per the mandate, the company is authorized to repurchase to repurchase CNY 100 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 90 per share. The repurchased shares will be cancelled. The program will be funded out of the company's own funds. The program will be valid till 1 months from the date of approval by shareholders.
お知らせ • Sep 27KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 100 million worth of its shares.KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 3 months.
お知らせ • May 30KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 100 million worth of its shares.KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 3 months.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Jie Li was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 29KBC Corporation, Ltd., Annual General Meeting, May 20, 2026KBC Corporation, Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: 1F, No. 79, Xiaoshitang Road, Yuelu District, Changsha, Hunan China
お知らせ • Mar 30KBC Corporation, Ltd. to Report Q1, 2026 Results on Apr 29, 2026KBC Corporation, Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
お知らせ • Dec 26KBC Corporation, Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026KBC Corporation, Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026
お知らせ • Sep 30KBC Corporation, Ltd. to Report Q3, 2025 Results on Oct 30, 2025KBC Corporation, Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025
お知らせ • Jun 30KBC Corporation, Ltd. to Report First Half, 2025 Results on Aug 29, 2025KBC Corporation, Ltd. announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • Apr 29KBC Corporation, Ltd., Annual General Meeting, May 20, 2025KBC Corporation, Ltd., Annual General Meeting, May 20, 2025, at 14:00 China Standard Time.
お知らせ • Mar 28KBC Corporation, Ltd. to Report Q1, 2025 Results on Apr 29, 2025KBC Corporation, Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
お知らせ • Dec 27KBC Corporation, Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025KBC Corporation, Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025
Reported Earnings • Oct 30Third quarter 2024 earnings released: CN¥0.21 loss per share (vs CN¥0.14 profit in 3Q 2023)Third quarter 2024 results: CN¥0.21 loss per share (down from CN¥0.14 profit in 3Q 2023). Revenue: CN¥97.3m (down 64% from 3Q 2023). Net loss: CN¥42.8m (down 248% from profit in 3Q 2023). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.
New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Sep 30KBC Corporation, Ltd. to Report Q3, 2024 Results on Oct 30, 2024KBC Corporation, Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024
お知らせ • Aug 09KBC Corporation, Ltd. (SHSE:688598) commences an Equity Buyback Plan for CNY 20 million worth of its shares, under the authorization approved on August 6, 2024.KBC Corporation, Ltd. (SHSE:688598) commences share repurchases on August 8, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on August 6, 2024. As per the mandate, the company is authorized to repurchase to repurchase CNY 20 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 35 per share. The shares repurchased will be used to reduce registered capital, used for employee stock ownership plan or equity incentive, used to convert company convertible bonds and to maintain company value and shareholder rights. The program will be funded out of the company's own funds. The program will be valid till 1 months from the date of approval by shareholders, i.e., till September 5, 2024.
お知らせ • Jun 28KBC Corporation, Ltd. to Report First Half, 2024 Results on Aug 30, 2024KBC Corporation, Ltd. announced that they will report first half, 2024 results on Aug 30, 2024
New Risk • May 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (31% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Profit margins are more than 30% lower than last year (3.1% net profit margin).
お知らせ • Apr 30KBC Corporation, Ltd., Annual General Meeting, May 20, 2024KBC Corporation, Ltd., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: 1F, No. 79, Xiaoshitang Road, Yuelu District, Changsha, Hunan China
Reported Earnings • Apr 29Full year 2023 earnings released: EPS: CN¥1.46 (vs CN¥4.36 in FY 2022)Full year 2023 results: EPS: CN¥1.46 (down from CN¥4.36 in FY 2022). Revenue: CN¥1.07b (down 26% from FY 2022). Net income: CN¥202.5m (down 63% from FY 2022). Profit margin: 19% (down from 38% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 65% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.
Valuation Update With 7 Day Price Move • Apr 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥42.45, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 66% over the past year.
お知らせ • Mar 29KBC Corporation, Ltd. to Report Q1, 2024 Results on Apr 29, 2024KBC Corporation, Ltd. announced that they will report Q1, 2024 results on Apr 29, 2024
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥55.50, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 54% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥96.72 per share.
お知らせ • Feb 27KBC Corporation, Ltd. (SHSE:688598) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on February 23, 2024.KBC Corporation, Ltd. (SHSE:688598) commences share repurchases on February 26, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on February 23, 2023. As per the mandate, the company is authorized to repurchase to repurchase CNY 100 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 90 per share. The repurchased shares will be cancelled. The program will be funded out of the company's own funds. The program will be valid till 1 months from the date of approval by shareholders.
Reported Earnings • Feb 24Full year 2023 earnings released: EPS: CN¥1.46 (vs CN¥4.36 in FY 2022)Full year 2023 results: EPS: CN¥1.46 (down from CN¥4.36 in FY 2022). Revenue: CN¥1.07b (down 26% from FY 2022). Net income: CN¥203.3m (down 63% from FY 2022). Profit margin: 19% (down from 38% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 55% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.
Valuation Update With 7 Day Price Move • Jan 31Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥45.84, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 14x in the Chemicals industry in China. Total loss to shareholders of 72% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥88.43 per share.
New Risk • Jan 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.8% average weekly change). High level of non-cash earnings (41% accrual ratio).
Buying Opportunity • Dec 11Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be CN¥91.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Earnings per share has grown by 23%. Revenue is forecast to grow by 201% in 2 years. Earnings is forecast to grow by 156% in the next 2 years.
New Risk • Nov 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (41% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).
Reported Earnings • Oct 24Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.98 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.21 (down from CN¥0.98 in 3Q 2022). Revenue: CN¥271.1m (down 9.7% from 3Q 2022). Net income: CN¥28.8m (down 78% from 3Q 2022). Profit margin: 11% (down from 43% in 3Q 2022). Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China.
お知らせ • Sep 27KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 100 million worth of its shares.KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 3 months.
Reported Earnings • Aug 15Second quarter 2023 earnings released: EPS: CN¥1.20 (vs CN¥1.39 in 2Q 2022)Second quarter 2023 results: EPS: CN¥1.20 (down from CN¥1.39 in 2Q 2022). Revenue: CN¥304.6m (down 23% from 2Q 2022). Net income: CN¥165.1m (flat on 2Q 2022). Profit margin: 54% (up from 42% in 2Q 2022). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.
お知らせ • Jun 28KBC Corporation, Ltd. to Report First Half, 2023 Results on Aug 29, 2023KBC Corporation, Ltd. announced that they will report first half, 2023 results on Aug 29, 2023
New Risk • Jun 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (53% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding).
お知らせ • May 30KBC Corporation, Ltd. (SHSE:688598) announces an Equity Buyback for CNY 100 million worth of its shares.KBC Corporation, Ltd. (SHSE:688598) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 3 months.
Reported Earnings • Apr 22Full year 2022 earnings released: EPS: CN¥6.45 (vs CN¥6.26 in FY 2021)Full year 2022 results: EPS: CN¥6.45 (up from CN¥6.26 in FY 2021). Revenue: CN¥1.45b (up 8.4% from FY 2021). Net income: CN¥551.2m (up 10.0% from FY 2021). Profit margin: 38% (in line with FY 2021). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.
Reported Earnings • Mar 01Full year 2022 earnings released: EPS: CN¥6.45 (vs CN¥6.26 in FY 2021)Full year 2022 results: EPS: CN¥6.45 (up from CN¥6.26 in FY 2021). Revenue: CN¥1.45b (up 8.4% from FY 2021). Net income: CN¥551.2m (up 10.0% from FY 2021). Profit margin: 38% (in line with FY 2021). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Hongbo Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥265, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 15x in the Chemicals industry in China.
Reported Earnings • Oct 30Third quarter 2022 earnings released: EPS: CN¥1.46 (vs CN¥1.63 in 3Q 2021)Third quarter 2022 results: EPS: CN¥1.46 (down from CN¥1.63 in 3Q 2021). Revenue: CN¥300.2m (down 20% from 3Q 2021). Net income: CN¥128.8m (down 1.3% from 3Q 2021). Profit margin: 43% (up from 35% in 3Q 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.
Reported Earnings • Aug 29Second quarter 2022 earnings released: EPS: CN¥2.06 (vs CN¥1.58 in 2Q 2021)Second quarter 2022 results: EPS: CN¥2.06 (up from CN¥1.58 in 2Q 2021). Revenue: CN¥396.3m (up 27% from 2Q 2021). Net income: CN¥165.3m (up 30% from 2Q 2021). Profit margin: 42% (up from 41% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 26%, compared to a 40% growth forecast for the Chemicals industry in China.
Valuation Update With 7 Day Price Move • Aug 02Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥381, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 18x in the Chemicals industry in China.
Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥330, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 17x in the Chemicals industry in China.
Valuation Update With 7 Day Price Move • May 02Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥214, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 15x in the Chemicals industry in China.
Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: CN¥2.53 (vs CN¥0.97 in 1Q 2021)First quarter 2022 results: EPS: CN¥2.53 (up from CN¥0.97 in 1Q 2021). Revenue: CN¥450.2m (up 126% from 1Q 2021). Net income: CN¥202.7m (up 163% from 1Q 2021). Profit margin: 45% (up from 39% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 21%, compared to a 43% growth forecast for the industry in China.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Hongbo Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Mar 08Investor sentiment deteriorated over the past weekAfter last week's 21% share price decline to CN¥222, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 18x in the Chemicals industry in China.
Reported Earnings • Feb 27Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: CN¥6.26 (up from CN¥2.35 in FY 2020). Revenue: CN¥1.34b (up 214% from FY 2020). Net income: CN¥501.1m (up 197% from FY 2020). Profit margin: 38% (down from 40% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 9.7%. Over the next year, revenue is forecast to grow 27%, compared to a 47% growth forecast for the industry in China.
Valuation Update With 7 Day Price Move • Jan 11Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥298, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 20x in the Chemicals industry in China.